Cargando…

Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally used for diabetes mellitus, are gaining more popularity for other indications, owing to their positive cardiovascular and renal effects. SGLT2 inhibitors reduce heart failure (HF) hospitalization and improve cardiovascular outcomes in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moady, Gassan, Ben Gal, Tuvia, Atar, Shaul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301138/ https://www.ncbi.nlm.nih.gov/pubmed/37374037 http://dx.doi.org/10.3390/life13061256

Ejemplares similares

Management of Patients with Left Ventricular Assist Device during the COVID-19 Pandemic
por: Moady, Gassan, et al.
Publicado: (2022)

Ventricular Assist Devices: Challenges of the One-device Era
por: Moady, Gassan, et al.
Publicado: (2022)

Takotsubo Syndrome During the COVID-19 Pandemic: State-of-the-Art Review
por: Moady, Gassan, et al.
Publicado: (2021)

Stress-Induced Cardiomyopathy—Considerations for Diagnosis and Management during the COVID-19 Pandemic
por: Moady, Gassan, et al.
Publicado: (2022)

The Prognostic Value of Natriuretic Peptides in Stable Patients with Suspected Acute Myocarditis: A Retrospective Study
por: Moady, Gassan, et al.
Publicado: (2022)

Cardiac assessment accuracy by students using palm-held ultrasound compared to physical examination by skilled cardiologists: a pilot study with a single medical student
por: Sarig, Shirley, et al.
Publicado: (2022)

The Role of Stress in Stable Patients with Takotsubo Syndrome—Does the Trigger Matter?
por: Moady, Gassan, et al.
Publicado: (2022)

The Role of Extracellular Signal-Regulated Kinase Pathways in Different Models of Cardiac Hypertrophy in Rats
por: Moady, Gassan, et al.
Publicado: (2023)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
por: Daud, Elias, et al.
Publicado: (2021)

The impact of on-site cardiac surgical backup on clinical outcomes of acute coronary syndrome—analysis of the ACSIS national registry
por: Moady, Gassan, et al.
Publicado: (2023)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians
por: Monzo, Luca, et al.
Publicado: (2023)

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
por: Joshi, Shruti S, et al.
Publicado: (2021)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
por: Angelini, Gianmarco, et al.
Publicado: (2021)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
por: Rosano, Giuseppe, et al.
Publicado: (2020)

Correction: Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Publicado: (2021)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
por: Oh, Jaewon, et al.
Publicado: (2021)

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
por: Alkagiet, Stelina, et al.
Publicado: (2020)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022)

Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials
por: Kato, Eri Toda, et al.
Publicado: (2020)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
por: Shen, Xizi, et al.
Publicado: (2022)

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia
por: Tang, Wen‐Jing, et al.
Publicado: (2023)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
por: Sharma, Abhinav, et al.
Publicado: (2019)

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
por: Kubica, Jacek, et al.
Publicado: (2023)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

The Mounting Evidence for Permissive Hypercreatinemia in Acute Heart Failure: Adding Sodium Glucose Cotransporter Inhibitors to the List
por: Macedo, Etienne, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
por: Iguchi, Moritake, et al.
Publicado: (2023)

Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
por: Naito, Ryo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oroaks9p1atsa9gdvnfu3h7f3s